|
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
- Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
Semaglutide at a dose of 2 4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2 4 mg has shown promising results in early-phase trials; the efficacy of the
- Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Zimislecel is an allogeneic stem cell–derived islet-cell therapy Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 . . .
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with
|
|
|